In a study with 1000 CRC patients with known BRAF and KRAS status, only 3 (0.3%) harbored both mutations simultaneously and those patients fared significantly worse in terms of OS and DFS compared to their wild type counterpart [25]. Here, KRAS is linked to colorectal carcinoma.